
A


REM vs Ctl ITT Patients < 65 Years
Absence of All Cause Death at Day 60
1.0
0.8
0.6
0.4
0.2
0.0
MSC
Control
All ITT Patients < 65 yrs (n=125)
REM 25.9% (15/58) vs Control 42% (28/67)
HR: 0.536; 95% CI (0.286, 1.005), p=0.051
Log Rank p-value = 0.0484
+ Censored
Control 67 63 52 45 40 39 39
MSC 58 56 53 48 46 43 42
0 10 20 30 40 50 60
Days from Day 0 Treatment
RANDTRT Control MSC

B



REM vs Ctl ITT Patients ≥ 65 Years
Absence of All Cause Death at Day 60
1.0
0.8
0.6
0.4
0.2
0.0
Control
MSC
All ITT Patients ≥65 yrs (n=97)
REM 72.2% (39/54) vs Control 69.8% (30/43)
Log Rank p-value = 0.791
+ Censored
Control 43 40 26 18 15 13 13
MSC 54 48 30 24 18 17 15
0 10 20 30 40 50 60
Days from Day 0 Treatment
RANDTRT Control MSC

FIGURE 1



A
Absence of All Cause Death at Day 60
1.0
0.8
0.6
0.4
0.2
0.0
MSC
Control
Mortality Through 60 Days
REM 26% (15/57) vs Control 42% (28/66)
HR: 0.536; 95% CI (0.286, 1.005), p=0.05
Log Rank p-value = 0.0483
+ Censored
Control 66 62 51 44 39 38 38
MSC 57 55 52 47 45 42 40
0 10 20 30 40 50 60
Days from Day 0 Treatment
RANDTRT Control MSC
B
Absence of All Cause Death at Day 60
1.0
0.8
0.6
0.4
0.2
0.0
MSC
Control
Mortality Through 60 Days
REM 72% (38/53) vs Control 71% (29/41)
HR: 1.053; 95% CI (0.649, 1.708), p=0.8332
Log Rank p-value = 0.8206
+ Censored
Control 43 40 26 18 15 13
MSC 54 48 30 24 19 17 15
0 10 20 30 40 50 60
Days from Day 0 Treatment
RANDTRT Control MSC

FIGURE 2




Treated Patients (mITT) < 65 years old (n=123)
Remestemcel-L vs Control
Respiratory Function Improvement: Patients < 65 years
% of Subjects Improved from Baseline
90%
70%
60%
50%
40%
30%
20%
10%
0%
Day 7
OR: 1.2
95% CI: 0.57, 2.4
Day14
OR: 2.1
95% CI: 1.0, 4.5
Day 21
OR: 1.9
95% CI: 0.90, 4.1
Day 30
OR: 2.2
95% CI: 1.0, 4.7
Rem-L
Placebo
Treated Patients (mITT) ≥ 65 years old (n=94)
Remestemcel-L vs Control
Respiratory Function Improvement: Patients ≥ 65 years
% of Subjects Improved from Baseline
Day 7
OR: 2.1
95% CI: 0.83, 5.1
Day14
OR: 1.1
95% CI: 0.43, 2.7
Day 21
OR: 0.94
95% CI: 0.38, 2.4
Day 30
OR: 0.75
95% CI: 0.30, 1.9
Rem-L
Placebo
* Measured as resolution and/or improvement of ARDS as defined by the Berlin criteria at Days 7, 14, 21, and 30 post-randomizations

FIGURE 3


CRP
log10CRP Trt14Days_All
Marginal means
3.2
3.1
3.0
2.9
2.8
0
3
7
14
day
**
treat
Placebo
MSC
CRP <65 yrs
y65
CRP >65 yrs
o65
Marginal means
3.4
3.2
3.0
2.8
2.6
*
**
**

A

FIGURE 4-1



B
Ferritin
log10Ferritin Trt14Days_All
Marginal means
3.6
3.5
3.4
3.3
3.2
0
3
7
14
day
Ferritin <65 yrs
y65
Ferritin >65 yrs
o65
treat
Placebo
MSC

FIGURE 4-2



C
D-Dimer
log10DDimer Trt14Days_All
Marginal means
4.3
4.2
4.1
4.0
3.9
3.8
0
3
7
14
day
treat
Placebo
MSC
D-Dimer <65 yrs
y65
D-Dimer >65 yrs
o65

FIGURE 4-3



color2bar
FDR Up
P Up
NS
P Down
FDR Down
Effect of Age (Continuous variable)
Effect of Corticosteroids Yes vs No
Effect of Age >65 vs <65
Effect of Age >65 vs <65 In Corticosteroid Users
M2_ageEffect
M2_corticoEffect
M3_ageEffectBin
M4_ageEffectBin_ContUsers
log2FCH
Analytes
IL17C
CCL7
IL10
CXCL10
TGFA
IL2
CCL11
CXCL8
CXCL9
IL15
CSF3
IL27
CXCL12
CCL3
IL33
CCL2
VEGFA
TNFSF12
TNFSF10
CCL4
CSF1
TSLP
IL18
OLR1
TNF
IL7
CXCL11
OSM
IL4
MMP1
CCL8
IL17F
MMP12
CCL19
IL17A
CCL13
EGF
IL6
CSF2
HGF
LTA
IL1B
IFNG
IL13
FLT3LG

FIGURE 5



Age <65 (N=120)
Age >=65 (N=93)
Delta7vs0_Placebo
Delta7vs0_MSC
Delta14vs0_Placebo
Delta14vs0_MSC
log2(FCH)
color2bar
FDR Up
P Up
NS
P Down
FDR Down
Analytes
FLT3LG
IL17A
MMP12
IL12
DLRT1
LTA
CCL13
CCL11
IL4
IL17F
IL13
TNFSF10
IL27
MMP1
EGF
TNFSF12
CSF1
IL5
CSF3
VEGFA
CCL3
TNF
CCL4
TGFA
CXCL12
CXCL8
IL2
CCL19
IL18
IL15
OSM
IL7
IL33
CSF2
TSLP
IL10
HGF
CXCL11
CXCL9
IL6
CCL8
IFNG
CCL7
CXCL10

FIGURE 6